Kintor Pharmaceutical Limited (KNTPF)
OTCMKTS · Delayed Price · Currency is USD
0.3643
+0.0349 (10.60%)
At close: Aug 18, 2025
Kintor Pharmaceutical Revenue
In the year 2024, Kintor Pharmaceutical had annual revenue of 5.00M CNY. Kintor Pharmaceutical had revenue of 5.00M in the half year ending December 31, 2024.
Revenue
5.00M CNY
Revenue Growth
n/a
P/S Ratio
202.26
Revenue / Employee
29.76K CNY
Employees
168
Market Cap
138.55M USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5.00M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 34.23M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Glass House Brands | 221.55M |
| Elite Pharmaceuticals | 105.45M |
| American Oncology Network | 1.76B |
| Northwest Biotherapeutics | 1.09M |
| Silence Therapeutics | 27.17M |
| Global Cord Blood | 196.10M |
Kintor Pharmaceutical News
- 2 years ago - Kintor Pharma Announces the Approval for Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China - PRNewsWire
- 2 years ago - Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China - PRNewsWire
- 2 years ago - Kintor Pharma Announces Completion of First Patient Enrollment in Long-term Safety Phase III Trial of KX-826 for Treatment of AGA - PRNewsWire
- 2 years ago - Kintor Pharma Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US - PRNewsWire
- 2 years ago - Kintor Pharma Announces 2022 Annual Results and Recent Business Progress - PRNewsWire
- 2 years ago - Kintor Pharma Announces Completion of Subject Enrollment in Phase III Clinical Trial of KX-826 for Treatment of Male Androgenetic Alopecia in China - PRNewsWire
- 2 years ago - Kintor Pharma's KX-826 and GT20029 for Treatment of Androgenetic Alopecia (AGA) and Acne Presented at AAD 2023 - PRNewsWire
- 2 years ago - Kintor Pharma Announces Positive Top-line U.S. Phase I Trial Results of GT20029, the World's First Topical Use PROTAC Compound - PRNewsWire